论文部分内容阅读
目的 探讨来氟米特 (leflunomide,LFM )治疗类风湿关节炎 (rheumatoidarthritis,RA)的疗效和安全性。方法 与甲氨喋呤 (methotrexate,MTX)对照 ,用随机双盲双模拟的研究方法将 80例活动性RA患者随机分为 2组 ,每组各 40例 ,分别接受LFM每日 2 0mg和MTX每周 10mg口服 ,疗程 2 4周 ,观察疗效和不良反应。结果 经治疗 12周时LFM和MTX组的总有效率分别为 77 5 %和 72 5 % (P >0 0 5 ) ,2 4周时分别为 86 5 %和 83 3% (P >0 0 5 ) ;2组不良反应及发生率相近 ,分别为 13 5 %和 2 5 0 % ,差异无显著性(P >0 1) ,LFM组不良反应程度相对较轻。结论 LFM治疗RA的疗效肯定 ,且具有较好的耐受性
Objective To investigate the efficacy and safety of leflunomide (LFM) in the treatment of rheumatoid arthritis (RA). Methods Eighty patients with active RA were randomly divided into two groups (40 patients in each group) by methotrexate (MTX) and methotrexate (MTX) Oral weekly 10mg, treatment 24 weeks, observe the efficacy and adverse reactions. Results The total effective rates of LFM and MTX group were 77.5% and 72.5% respectively after 12 weeks of treatment (P> 0.05), and were 86.5% and 83.3% respectively at 24 weeks (P> 0.05 ). There were no significant differences between the two groups (P> 0.05) and the incidence of adverse reactions in the two groups (13.5% and 25.0%, respectively). The adverse reactions in LFM group were relatively mild. Conclusions The efficacy of LFM in the treatment of RA is definite and well tolerated